Most Read

The approval will enable ViiV Healthcare to use the complete regimen as a replacement for the current antiretroviral (ARV) regimen in adults who are virologically suppressed on a

BLENREP has been approved as a monotherapy treatment for adult patients with relapsed or refractory multiple myeloma who have secured at least four prior therapies including an anti-CD38

Sisunatovir is an orally administered fusion inhibitor designed to inhibit RSV replication by suppressing RSV F-mediated fusion of RSV with the host cell. RSV is a respiratory pathogen

MDS is a rare form of bone marrow-related cancer, which will be resulted due to irregular blood cell production within the bone marrow. Pevonedistat, a first-in-class NEDD8-activating enzyme

The phase III COVACTA study of tocilizumab did not reach its primary endpoint of improved clinical status in hospitalised adult patients with severe Covid-19 associated pneumonia. Roche’s trial

The US technology company signed a letter of interest (LOI) with the DFC to secure a loan to establish Kodak Pharmaceuticals, a new business unit that will engage

Both companies have decided to advance their BNT162b2 vaccine candidate into the phase 2/3 study at a 30µg dose level in a two-dose regimen after an extensive assessment

Currently, DS-1062 is being developed for the treatment of non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC). The TROP2 directed DXd antibody drug conjugate (ADC) is

Tecartus, earlier known as KTE-X19, is claimed to be the first and only approved chimeric antigen receptor (CAR) T cell therapy to treat relapsed or refractory MCL. Tecartus,